3-Quinuclidinyl benzilate (BZ) ranks among incapacitating military warfare agents. It acts as a competitive inhibitor on muscarinic receptors leading to non-lethal mental impairment. The present study aimed to investigate toxicokinetics of BZ in rats. Moreover, BZ can be exploited to produce a pharmacological model of Alzheimer's disease; thus, this paper focuses mainly on the BZ distribution to the brain. Wistar rats were administered i.p. with BZ (2 and 10 mg/kg). The BZ concentration was determined using LC-MS/MS in plasma, urine, bile, brain, kidney and liver. The sample preparation was based on a solid phase extraction (liquids) or protein precipitation (organ homogenates). The plasma concentration peaked at 3 min (204.5 ± 55.4 and 2185.5 ± 465.4 ng/ml). The maximal concentration in the brain was reached several minutes later. Plasma elimination half-life was 67.9 ± 3.4 in the 2 mg/kg group and 96.6 ± 27.9 in the 10 mg/kg group. BZ concentrations remained steady in the brain, with slow elimination (t1/2 506.9 ± 359.5 min). Agent BZ is excreted mainly via the urine. Steady BZ concentration in the brain could explain the previously published duration of the significant impairment in passive avoidance tasks in rats after an injection of BZ.

Department of Medical Biochemistry Faculty of Medicine in Hradec Kralove Charles University Prague Czech Republic

Department of Pharmaceutical Chemistry and Pharmaceutical Analysis Faculty of Pharmacy Charles University Prague Czech Republic

Department of Toxicology and Military Pharmacy Faculty of Military Health Sciences in Hradec Kralove University of Defence Brno Czech Republic

See more in PubMed

OPCW. Incident in Salisbury. https://www.opcw.org/media-centre/featured-topics/incident-salisbury. Accessed April 24, 2020.

Gupta RC. Handbook of Toxicology of Chemical Warfare Agents. Academic Press; 2020.

OPCW. Chemical weapons convention. https://www.opcw.org/chemical-weapons-convention. Accessed April 22, 2020.

Misík J. Military incapacitating agent BZ (3-quinuclidinyl benzilate)-past, present and future. MMSL. 2013;82(3):115-119. https://doi.org/10.31482/mmsl.2013.016

United Nations. As security council hotly debates new report on Salisbury nerve agent attack, some members call for action to identify, apprehend perpetrators. Meetings Coverage and Press Releases. https://www.un.org/press/en/2018/sc13304.doc.htm. Accessed April 24, 2020.

Mukherjee R, Trimmer BA. Local and generalized sensitization of thermally evoked defensive behavior in caterpillars. J Comp Neurol. 2020;528(5):805-815. https://doi.org/10.1002/cne.24797

Więckowska A, Gajewska-Woźniak O, Głowacka A, et al. Spinalization and locomotor training differentially affect muscarinic acetylcholine receptor type 2 abutting on α-motoneurons innervating the ankle extensor and flexor muscles. J Neurochem. 2018;147(3):361-379. https://doi.org/10.1111/jnc.14567

Carr BJ, Mihara K, Ramachandran R, et al. Myopia-inhibiting concentrations of muscarinic receptor antagonists block activation of Alpha2A-adrenoceptors in vitro. Invest Ophthalmol Vis Sci. 2018;59(7):2778-2791. https://doi.org/10.1167/iovs.17-22562

Silva MFP, Alves PL, Alponti RF, Silveira PF, Abdalla FMF. Effects of obesity induced by high-calorie diet and its treatment with exenatide on muscarinic acetylcholine receptors in rat hippocampus. Biochem Pharmacol. 2019;169:113630. https://doi.org/10.1016/j.bcp.2019.113630

Inoue O, Sato T, Kobayashi K, Gee A, Shukuri M, Zhang M-R. Unexpected decrease in in vivo binding of [3H]QNB in the mouse cerebral cortex in the developing brain-a comparison with [11C]NMPB. Nucl Med Biol. 2018;67:15-20. https://doi.org/10.1016/j.nucmedbio.2018.10.004

Misik J, Korabecny J, Nepovimova E, Kracmarova A, Kassa J. Effects of novel tacrine-related cholinesterase inhibitors in the reversal of 3-quinuclidinyl benzilate-induced cognitive deficit in rats-is there a potential for Alzheimer's disease treatment? Neurosci Lett. 2016;612:261-268. https://doi.org/10.1016/j.neulet.2015.12.021

Misik J, Korabecny J, Nepovimova E, Cabelova P, Kassa J. The effects of novel 7-MEOTA-donepezil like hybrids and N-alkylated tacrine analogues in the treatment of quinuclidinyl benzilate-induced behavioural deficits in rats performing the multiple T-maze test. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015;159(4):547-553. https://doi.org/10.5507/bp.2015.006

Tveden-Nyborg P, Bergmann TK, Jessen N, Simonsen U, Lykkesfeldt J. BCPT policy for experimental and clinical studies. Basic Clin Pharmacol Toxicol. 2021;128(1):4-8. https://doi.org/10.1111/bcpt.13492

Misik J, Vanek J, Musilek K, Kassa J. Cholinergic antagonist 3-quinuclidinyl benzilate - Impact on learning and memory in Wistar rats. Behav Brain Res. 2014;266:193-200. https://doi.org/10.1016/j.bbr.2014.03.001

Herman D, Dlabkova A, Cechova L, et al. Simple validated method of LC-MS/MS determination of BZ agent in rat plasma samples. Drug Test Anal. Published Online November 30, 2019;(4):431-438. https://doi.org/10.1002/dta.2742

Zemek F, Zdarova JK, Sepsova V, Kuca K. Acetylcholinesterase reactivators (HI-6, obidoxime, trimedoxime, K027, K075, K127, K203, K282): structural evaluation of human serum albumin binding and absorption kinetics. Int J Mol Sci. 2013;14(8):16076-16086. https://doi.org/10.3390/ijms140816076

European Medicines Agency. 2011. guideline-bioanalytical-method-validation_en.pdf. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-method-validation_en.pdf. Accessed March 21, 2020.

Uher M, Mžik M, Karasová JŽ, et al. In vitro and in vivo metabolism of 3-quinuclidinyl benzilate by high-resolution mass spectrometry. J Pharm Biomed Anal. 2020;190:113519. https://doi.org/10.1016/j.jpba.2020.113519

Byrd GD, Paule RC, Sander LC, Sniegoski LT, White E, Bausum HT. Determination of 3-quinuclidinyl benzilate (QNB) and its major metabolites in urine by isotope dilution gas chromatography/mass spectrometry. J Anal Toxicol. 1992;16(3):182-187. https://doi.org/10.1093/jat/16.3.182

Misik J, Kassa J. A comparison of cholinesterase inhibitors in the treatment of quinuclidinyl benzilate-induced behavioural deficit in rats performing the multiple T-maze. Journal of Applied Biomedicine. 2014;12(4):211-217. https://doi.org/10.1016/j.jab.2014.01.006

Greaves I, Hunt P. Responding to Terrorism 1st Edition A Medical Handbook. 1. Churchill Livingstone; 2011.

Kulkarni AD, Patel HM, Surana SJ, Belgamwar VS, Pardeshi CV. Brain-blood ratio: implications in brain drug delivery. Expert Opin Drug Deliv. 2016;13(1):85-92. https://doi.org/10.1517/17425247.2016.1092519

Gibson RE, Eckelman WC, Vieras F, Reba RC. The distribution of the muscarinic acetylcholine receptor antagonists, quinuclidinyl benzilate and quinuclidinyl benzilate methiodide (both tritiated), in rat, guinea pig, and rabbit. J Nucl Med. 1979;20(8):865-870.

Abrams P, Andersson K-E, Buccafusco JJ, et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol. 2006;148(5):565-578. https://doi.org/10.1038/sj.bjp.0706780

Angelis K, Bardoděj Z, Samcová E, Šrám R. Studium časového průběhu účinku a hladiny látky BZ a benzilátů po intraperitoneální aplikaci u krys. Published online 1975.

Cornelissen AS, Klaassen SD, van Groningen T, Bohnert S, Joosen MJA. Comparative physiology and efficacy of atropine and scopolamine in sarin nerve agent poisoning. Toxicol Appl Pharmacol. Published online April 3, 2020;114994. https://doi.org/10.1016/j.taap.2020.114994